Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
C4 Therapeutics ( (CCCC) ) just unveiled an announcement.
On May 7, 2025, C4 Therapeutics announced updates from its Phase 1 clinical trial of cemsidomide, a small-molecule degrader for multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL). The trial’s dose escalation phase in MM is complete, with the 100 µg QD dose level showing a 50% overall response rate, including a complete response in one patient. The trial continues for NHL, with the maximum tolerated dose not yet reached. C4T plans to prioritize cemsidomide’s development and expects regulatory feedback by mid-2025 to support further clinical development in 2026. Financially, C4T reported a net loss of $26.3 million for Q1 2025, with cash reserves expected to fund operations into 2027.
Spark’s Take on CCCC Stock
According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral.
C4 Therapeutics faces significant challenges with profitability and operational inefficiencies, leading to a low financial performance score. Technical analysis indicates bearish momentum, further weighing down the overall stock score. Valuation is constrained by negative earnings, making the stock less attractive. Without earnings call insights or notable corporate events, the score reflects the company’s current financial and market challenges.
To see Spark’s full report on CCCC stock, click here.
More about C4 Therapeutics
C4 Therapeutics (C4T) is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science to develop innovative medicines. The company is engaged in targeted oncology programs and utilizes its TORPEDO® platform to design small-molecule medicines aimed at difficult-to-treat diseases, particularly in oncology.
Average Trading Volume: 1,232,696
Technical Sentiment Signal: Sell
Current Market Cap: $100.1M
Learn more about CCCC stock on TipRanks’ Stock Analysis page.